Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,972,736

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (32 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance

Eli Lilly's (LLY) stock rallies after it raises 2021 profit and sales outlook and provides an upbeat financial guidance for the next year.

Lilly (LLY) Stock Jumps 10.4%: Will It Continue to Soar?

Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More

Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.

Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal

Eli Lilly's (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Foghorn (FHTX) Surges on Oncology Collaboration With Lilly

Foghorn (FHTX) soars following a collaboration with pharma giant Lilly for novel oncology targets.

Company News for Dec 14, 2021

Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $248.53, moving +1.8% from the previous trading session.

Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal

Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod

Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.

AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug

With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.

Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.

Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19

The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.

AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label

AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.

Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids

With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.

Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote

An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.

Mark Vickery headshot

Top Research Reports for Mastercard, Pfizer & Nike

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Pfizer Inc. (PFE), and NIKE, Inc. (NKE).

Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down

Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.

Lilly (LLY) Up 4.7% Since Last Earnings Report: Can It Continue?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote

Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.

Glaxo (GSK), Vir to Supply COVID Drug Sotrovimab to Government

Glaxo (GSK) and Vir Biotechnology (VIR) sign purchase contract with the U.S. government to supply doses of sotrovimab worth approximately $1 billion by next month.

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer and Novo Nordisk

Pfizer (PFE) Seeks FDA's Emergency Use Nod for COVID Pill

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially in mild-to-moderate COVID-19 patients at increased risk of hospitalizations or death.

Kinjel Shah headshot

3 Big Pharma Outperformers to Watch Out For in the Near Term

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP